Conclusions: A significant reduction in sTWEAK and increment in CD163 plasma levels were observed in patients with more severe atherosclerosis. Our results indicate that sTWEAK could be a novel biomarker of atherosclerotic burden in CKD patients.
PMID: 23475462 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)